HIGHLIGHTS
- who: Yuan-ke Liang from the Università di Padova, Italy Agostino Gemelli University Polyclinic have published the research work: CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer, in the Journal: (JOURNAL)
- what: Unfortunately, the number of breast cancer patients receiving immunotherapy is relatively small and the follow-up time for the study demonstrated that the level of CXCL9 was associated with the abundance of immune cell infiltration in breast cancer, which partially validated the expression of CXCL9 in this particular cancer being related to changes in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.